RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Iloperidone for the Treatment of Schizophrenia—Selected Posters
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 3
SP 15
OP 15
DO 10.1177/155989770800800311
UL http://mdc.sagepub.com/content/8/3/15.1.abstract
AB Over 50% of schizophrenia patients drop out of controlled trials within 6 months due to lack of efficacy or in some cases tolerability issues [Liu-Siefert et al. BMC Med 2005; Lieberman JA et al. N Engl J Med 2005], particularly extrapyramidal symptoms (EPS), akathisia, weight gain, metabolic effects, sedation, and anticholinergic effects. EPS and akathisia effects carry an increased risk of suicide [Dong JY et al. J Affect Disord 2005] and poor adherence, while metabolic effects can increase the risk for diabetes and cardiovascular disease. Iloperidone, a mixed D2/5-HT2 antagonist that is under US Federal Drug Administration (FDA) review, may provide a lower EPS/akathisia liability.